Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$0.14 - $12.49 $88,566 - $7.9 Million
632,618 Added 148.17%
1,059,582 $158,000
Q3 2022

Nov 14, 2022

BUY
$8.51 - $13.6 $649,866 - $1.04 Million
76,365 Added 21.78%
426,964 $4.48 Million
Q2 2022

Aug 15, 2022

BUY
$7.31 - $11.85 $37,566 - $60,897
5,139 Added 1.49%
350,599 $3.39 Million
Q1 2022

May 16, 2022

SELL
$7.35 - $10.63 $161,185 - $233,115
-21,930 Reduced 5.97%
345,460 $2.84 Million
Q4 2021

Feb 14, 2022

BUY
$4.19 - $9.56 $968,166 - $2.21 Million
231,066 Added 169.5%
367,390 $3.51 Million
Q3 2021

Nov 15, 2021

SELL
$3.56 - $4.64 $967,939 - $1.26 Million
-271,893 Reduced 66.61%
136,324 $633,000
Q2 2021

Aug 16, 2021

SELL
$3.95 - $5.41 $1.31 Million - $1.79 Million
-330,732 Reduced 44.76%
408,217 $1.76 Million
Q1 2021

May 17, 2021

BUY
$4.52 - $7.8 $2.05 Million - $3.54 Million
453,342 Added 158.73%
738,949 $3.91 Million
Q4 2020

Feb 16, 2021

BUY
$4.37 - $9.46 $505,381 - $1.09 Million
115,648 Added 68.04%
285,607 $2.01 Million
Q3 2020

Nov 16, 2020

SELL
$8.56 - $26.93 $85,788 - $269,892
-10,022 Reduced 5.57%
169,959 $1.54 Million
Q2 2020

Aug 14, 2020

BUY
$21.21 - $31.55 $1.87 Million - $2.77 Million
87,952 Added 95.57%
179,981 $4.95 Million
Q1 2020

May 15, 2020

BUY
$18.43 - $38.04 $893,431 - $1.84 Million
48,477 Added 111.31%
92,029 $2.03 Million
Q4 2019

Feb 14, 2020

SELL
$29.6 - $43.71 $178,014 - $262,871
-6,014 Reduced 12.13%
43,552 $1.64 Million
Q3 2019

Nov 14, 2019

BUY
$29.87 - $42.22 $1.48 Million - $2.09 Million
49,566 New
49,566 $1.53 Million

Others Institutions Holding TCDA

About Tricida, Inc.


  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.